Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases

Annals of the Rheumatic Diseases

Volumn 63, Issue 4, 2004, Pages 415-419

  Dubucquoi, S ^a,b   Solau Gervais, E ^b   Lefranc, D ^b   Marguerie, L ^c   Sibilia, J ^d   Goetz, J ^d   Dutoit, V ^b   Fauchais, A L ^b   Hachulla, E ^b   Flipo, R M ^b   Prin, L ^b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Institut Calot Helio Marin   (France)

^d HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FILAGGRIN; FILAGGRIN ANTIBODY; KERATIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RELIABILITY; RHEUMATIC DISEASE;

ANTIBODIES; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CITRULLINE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; INTERMEDIATE FILAMENT PROTEINS; KERATINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; REAGENT KITS, DIAGNOSTIC; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY; SJOGREN'S SYNDROME;

EID: 11144357807     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.008623     Document Type: Article

References (35)

1. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-5.
2. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
4. Simon M, Girbal E, Sebbag M, Gomes-Daudrix V, Vincent C, Salama G, et al. The cytokeratin filament-aggregating protein filaggrin is the target of the socalled "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993;92:1387-93.
5. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
6. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999;162:585-94.
7. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
8. Masson-Bessiere C, Sebbag M, Girbol-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha-and beta-chains of fibrin. J Immunol 2001;166:4177-84.
9. Bas S, Perneger TV, Mikhnevitch E, Seitz M, Tiercy JM, Roux-Lombard P, et al. Association of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis. Rheumatology (Oxf) 2000;39:1082-8.
10. Hill JA, Jevnikor AM, Bell DA, Cairns E. The role of HLA-DRB1*0401 MHC class II in autoimmune response to citrullinated antigens [abstract]. Arthritis Rheum 2002;46:745A.
11. Hill JA, Jevnikar AM, Bell DA, Cairns E. Citrullinated vimentin and fibrinogen peptides activate CD4+ T cells in HLA-DRB1*0401 transgenic mice [abstract]. Arthritis Rheum 2002;46:746A.
12. Ferraro-Peyret C, Tebib J, Desbas A, Bihannic R, Genestier C, Letroublon MC, et al. Improvement in diagnosis of rheumatoid arthritis using dual indirect immunofluorescence and immunoblotting assays for antifilaggrin autoantibodies: a retrospective 3 year study. J Rheumatol 2002;29:276-81.
13. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
14. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early second line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
15. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
16. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25:1072-7.
17. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
18. Buckland-Wright JC, Clarke GS, Chikanza IC, Grahame R. Quantitative microfocal radiography detects changes in erosion area in patients with early rheumatoid arthritis treated with myocrisine. J Rheumatol 1993;20:243-7.
19. Munro R, Hampson R, McEntegart A, Thomson EA, Madhok R, Capell H. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998;57:88-93.
20. Wolfe F. A comparison of IgM rheumatoid factor by nephelometry and latex methods: clinical and laboratory significance. Arthritis Care Res 1998;11:89-93.
21. Cervera R, Font J, Ramos-Casals M, Garcia-Carrasco M, Rosas J, Morla RM, et al. Primary Sjogren's syndrome in men: clinical and immunological characteristics. Lupus 2000;9:61-4.
22. Cordonnier C, Meyer O, Palazzo E, de Bandt M, Elias A, Nicaise P, et al. Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 1996;35:620-4.
23. Vasiliauskiene L, Wiik A, Hoier-Madsen M. Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:459-66.
24. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-43.
25. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
26. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001;47:1089-93.
27. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6.
28. Berthelot JM, Maugars Y, Prost A, Youinou P. Rheumatoid arthritis and filaggrin. A review. Rev Rhum Engl Ed 1995;62:127-38.
29. Slack SL, Mannik M, Dale BA. Diagnostic value of antibodies to filaggrin in rheumatoid arthritis. J Rheumatol 1998;25:847-51.
30. Vincent C, de Keyser F, Masson-Bessiere C, Sebbag M, Veys EM, Serre G. Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides. Ann Rheum Dis 1999;58:42-8.
31. Saraux A, Berthelot JM, Chales G, Le Henaff C, Mary JY, Thorel JB, et al. Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 2002;47:155-65.
32. Union A, Meheus L, Humbel RL, Conrad K, Steiner G, Moereels H, et al. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum 2002;46:1185-95.
33. Palosuo T, Tilvis R, Strandberg T, Aho K. Filaggrin related antibodies among the aged. Ann Rheum Dis 2003;62:261-3.
34. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxf) 2002;41:809-14.
35. Vasishta A. Diagnosing early-onset rheumatoid arthritis: the role of anti-CCP antibodies. Am Clin Lab 2002;21:34-6.